Stereotaxis Inc. said its MAGiC catheter is now being utilized at 12 U.S. sites [1].
The expansion of the MAGiC catheter program indicates a shift in the adoption rate of the company's robotic-assisted technology. As more hospitals integrate these tools, the company aims to increase the volume of procedures performed using its proprietary system.
During a virtual conference call held on Tuesday, the medical device company detailed its operational updates for the second quarter ending June 30 [1]. Executives said the adoption of the MAGiC catheter is accelerating [2]. This growth is a key metric for the company as it seeks to scale its presence in the U.S. healthcare market.
The reported 12 sites [1] represent the current footprint of the technology's active deployment. The company used the earnings call to provide a comprehensive update on financial performance, and the progress of its catheter program [2].
Stereotaxis continues to focus on the deployment of its robotic systems to improve precision in medical procedures. The current growth in site adoption serves as a primary indicator of the market's reception to the MAGiC system [1].
“MAGiC catheter is now being utilized at 12 U.S. sites”
The increase in active sites for the MAGiC catheter suggests that Stereotaxis is moving from a pilot phase into a broader commercial scaling phase. For the medical device industry, the success of this rollout will determine if robotic-assisted catheterization can achieve widespread clinical acceptance over traditional manual methods.
